Collectively these data demonstrate SOX2, PRRX1, and OCT2 are downstream effectors of SETD2 EMT and stemness pathways that are also relevant to ccRCC patient outcome. The gene discussed is SOX2; the disease is nonpapillary renal cell carcinoma.